Fig. 2
BAIAP2L2 up-regulation promotes platinum-based chemoresistance in GC. A qPCR showed the expression of BAIAP2L2, TRIM15, TRIM29, KRTCAP3 and GPR35 in DDP-resistant GC cells and DDP-sensitive cells. B Western Blot showed the expression of BAIAP2L2 in DDP-resistant GC cells and DDP-sensitive cells. C Western blot confirmed BAIAP2L2 was knocked down. D-F CCK-8 were used to explore the effect of BAIAP2L2 on the resistance to platinum chemotherapeutics of GC cells. Data of CCK-8 assays were analyzed by 2-way ANOVA. G The subcutaneous tumors from the BALB/c Nude mice injected LV-Ctrl or LV-Baiap2l2 MKN45/DDP cells, with DDP treatment (DDP 5 mg/kg once per week). H Weight and volume of subcutaneous tumors. Data on subcataneous tumor volume were analyzed by 2-way ANOVA. I-J Immunohistochemistry (IHC) staining were performed to detect the expression of BAIAP2L2 in GC tissues of patients resistant or sensitive to Platinum-based treatment. Scale bars for 20 × figures are 100 μm, and those for 40 × figures are 50 μm. The P value was calculated with the chi-square test (χ2)